The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 401–500 of 1,003
Sheu, S., Kaya, T., Waxman, D. J., & Vajda, S. (2004) · Biochemistry · doi:10.1021/bi048032c · Cited by 87
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Vella, V., Nicolosi, M. L., Giuliano, S., Bellomo, M., Belfiore, A., & Malaguarnera, R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00031 · Cited by 91
“PPAR agonists have different affinities for PPARs, various pharmacokinetic profiles, and specific gene expression profiles (64, 65).”
BackgroundMinireview: Genomics Versus Orphan Nuclear Receptors--A Half-Time Report
Willson, T. M. (2002) · Molecular Endocrinology · doi:10.1210/me.16.6.1135 · Cited by 82
Self-citationThiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis
Colmers, I. N., Bowker, S. L., & Johnson, J. A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.06.003 · Cited by 81
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 82
d'Abramo, C., Massone, S., Zingg, J.-M., Pizzuti, A., Marambaud, P., Dalla Piccola, B., Azzi, A., Marinari, U. M., Pronzato, M. A., & Ricciarelli, R. (2005) · Biochemical Journal · doi:10.1042/bj20050560 · Cited by 81
PPAR agonists in the treatment of atherosclerosis
Francis, G. A., Annicotte, J.-S., & Auwerx, J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00014-6 · Cited by 88
High-throughput screening using the surface plasmon resonance effect of colloidal gold nanoparticles
Englebienne, P., Verhas, M., & Hoonacker, A. V. (2001) · The Analyst · doi:10.1039/b105252g · Cited by 89
PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption
Ferguson, L. B., Most, D., Blednov, Y. A., & Harris, R. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.024 · Cited by 82
“, 2008) and 2) as a ratio of dose to the half maximal effective concentration (EC50) required for subtype-specific action (Ljung et al., 2002; Willson et al., 2000) (Table S6).”
Ravid, Z., Bendayan, M., DELVIN, E. E., Sané, A. T., Elchebly, M., Lafond, J., Lambert, M. A., Mailhot, G., & Levy, E. H. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90376.2008 · Cited by 90
PPARγ and metabolism: insights from the study of human genetic variants
Gurnell, M. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01767.x · Cited by 89
“…rosiglitazone has been shown to lower FFA and possibly triglycerides whilst raising LDL levels, with variable effects reported on HDL cholesterol (Willson et al., 2000; Boyle et al., 2002); in contrast, pioglitazone lowers triglycerides and LDL cholesterol whilst increasing HDL levels, thereby…”
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Patel, C. B., Wyne, K. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.010 · Cited by 80
Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E. H., Ruijtenbeek, R., & Kalkhoven, E. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900209-mcp200 · Cited by 91
“Using the peroxisome proliferator-activated receptor (PPAR ) as a model NR, we were able to generate ligand-specific interaction profiles (agonist rosiglitazone versus antagonist GW9662 versus selective PPAR modulator telmisartan) and characterize NR mutants and isotypes (PPAR , - / , and - ).”
MethodInfluentialVuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology
Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 85
Harrington, W. W., Britt, C. S., Wilson, J. G., Milliken, N. O., Binz, J. G., Lobe, D. C., Oliver, W. R., Lewis, M. C., & Ignar, D. M. (2007) · PPAR Research · doi:10.1155/2007/97125 · Cited by 74
“The discovery that fibrates are hypolipidemic agents which activate PPARα suggested that this receptor may play a role in lipid metabolism [9, 10].”
BackgroundShi, G. Q., Dropinski, J. F., McKeever, B. M., Xu, S., Becker, J. W., Berger, J. P., MacNaul, K. L., Elbrecht, A., Zhou, G., Doebber, T. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502135 · Cited by 87
Grøntved, L., Madsen, M. S., Boergesen, M., Roeder, R. G., & Mandrup, S. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01238-09 · Cited by 74
“The activity of AF-2 is regulated by the binding of ligands, such as fatty acids, fatty acid derivatives, and a number of synthetic agonists and antagonists (64).”
BackgroundPPAR agonists modulate human osteoclast formation and activity in vitro
Chan, B. Y., Gartland, A., Wilson, P. J. M., Buckley, K. M., Dillon, J. P., Fraser, W. D., & Gallagher, J. A. (2006) · Bone · doi:10.1016/j.bone.2006.07.029 · Cited by 86
“Isoform-specific PPAR agonists (GW9578, L165041 and ciglitizone) [4,31–33] gave selective strong effects on osteoclast formation and variable effects on resorption.”
BackgroundInfluentialSumanasekera, W. K., Tien, E. S., Davis, J. W., Turpey, R., Perdew, G. H., & Vanden Heuvel, J. P. (2003) · Biochemistry · doi:10.1021/bi0347353 · Cited by 78
Chakrabarti, R., Vikramadithyan, R. K., Misra, P., Hiriyan, J., Raichur, S., Damarla, R. K. B., Gershome, C., Suresh, J., & Rajagopalan, R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705463 · Cited by 83
Deng, X.-C., Zhang, P., Liang, T., Deng, S., Chen, X.-J., & Zhu, L. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2230 · Cited by 68
“PPAR γ can be activated by natural and synthetic ligands, such as 15d-PGJ2 (33), antidiabetic thiazolidinediones (TZDs) and the GW1929 compound (34).”
Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway
Li, T., Zhang, Q., Zhang, J., Yang, G. S., Shao, Z., Luo, J., Fan, M., Chen, N., Wu, Z., & Hu, X. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-96 · Cited by 78
“found that the human half maximal effective concentration (EC50) of fenofibrate was about 30 μM, and all PPAR-α agonists demanded such high micromolar concentration to activate PPAR-α ligands, which might explain why high doses were clinically needed [50].”
BackgroundPark, J. H., Lee, S. H., Chung, I.-M., & Park, Y. (2012) · Nutrition Research and Practice · doi:10.4162/nrp.2012.6.4.322 · Cited by 78
Michel, M. C., Brunner, H. R., Foster, C. J., & Huo, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.019 · Cited by 84
“In rat femoral arteries telmisartan but not losartan reduced phenylephrine vasoconstriction and enhanced acetylcholine induced vasodilatation, and the telmisartan effects were blocked by GW9662 (Siarkos et al., 2011).”
MethodInfluentialNielsen, R., Grøntved, L., Stunnenberg, H. G., & Mandrup, S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02266-05 · Cited by 77
“However, since many of the nuclear receptors, including the PPARs, are considered to be metabolic sensors activated by lipid metabolites produced within the cells (14, 68), the agonist concentration is difficult to control.”
BackgroundGuo, L., Zhang, L., Sun, Y. A., Muskhelishvili, L., Blann, E., Dial, S. L., Shi, L. M., Schroth, G. P., & Dragan, Y. P. (2006) · Molecular Diversity · doi:10.1007/s11030-006-9038-0 · Cited by 77
“ing insulin sensitivity in fat and muscle via the activation of the peroxisome proliferator-activated receptor γ (PPARγ ), a ligand-activated transcription factor of the nuclear hormone receptor superfamily [ 4 ].”
BackgroundThe vascular biology of atherosclerosis
Plutzky, J. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.010 · Cited by 96
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 86
Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.
Kopelovich, L., Fay, J. R., Glazer, R. I., & Crowell, J. A. (2002) · PubMed · Cited by 83
Pharmacological approaches to the treatment of diabetic complications
Costantino, L., Rastelli, G., Gamberini, M. C., & Barlocco, D. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.8.1245 · Cited by 87
“The PPARs: from orphan receptors to drug discovery.”
BackgroundInfluentialPeroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise
Sertznig, P., & Reichrath, J. (2011) · Dermato-Endocrinology · doi:10.4161/derm.15025 · Cited by 67
“Activation of the PPARs have been shown to play an important role in the regulation of energy homeostasis by modulating glucose and lipid metabolism and transport.(4) Moreover recent studies have demonstrated that PPARs regulate important cellular functions in the skin and other organs, including inflammation, immune…”
BackgroundYi, L., He, J., Liang, Y., Yuan, D., Gao, H., & Zhou, H. (2007) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2007.08.002 · Cited by 76
Theocharis, S. E., Kanelli, H., Politi, E. N., Margeli, A. P., Karkandaris, C., Philipides, T., & Koutselinis, A. S. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00013-2 · Cited by 84
“The PPAR-g protein shows a remarkable conservation across all the species from which it has been cloned, in contrast to that reported for PPAR-a and -b, reflecting its pivotal role in glucose and lipid homeostasis [46].”
BackgroundResultInfluentialBetz, M. J., Shapiro, I., Faßnacht, M., Hahner, S., Reincke, M., & Beuschlein, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1267 · Cited by 76
Roth, A. D., Leisewitz, A. V., Jung, J. E., Cassina, P., Barbeito, L., Inestrosa, N. C., & Bronfman, M. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10596 · Cited by 77
“As shown in Figure 3d, PPAR agonists (50 M TGZ or 10 M RGZ) enhance B12 process extension in a timedependent manner, an effect that was blocked clearly by adding the PPAR antagonist GW9662 (Willson et al., 2000) to the culture medium.”
BackgroundNovel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 77
ORAL THERAPIES FOR DIABETIC HYPERGLYCEMIA
Lebovitz, H. E. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70221-8 · Cited by 79
Plutzky, J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00614-3 · Cited by 82
Olson, E. J., Pearce, G. L., Jones, N. P., & Sprecher, D. L. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.247890 · Cited by 71
Pharmacophore modeling and parallel screening for PPAR ligands
Markt, P., Schuster, D., Kirchmair, J., Laggner, C., & Langer, T. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9140-0 · Cited by 74
Joner, M., Farb, A. A., Cheng, Q., Finn, A. V., Acampado, E., BURKE, A. P., Skorija, K., Creighton, W., Kolodgie, F. D., Gold, H. K., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000251021.28725.e8 · Cited by 74
Fenofibrate: Metabolic and Pleiotropic Effects
Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S., Mikhailidis, D., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 74
“PPAR modulate the expression of genes involved in lipid metabolism through PPAR response elements [75-77].”
BackgroundAt the interface of antioxidant signalling and cellular function: Key polyphenol effects
Kerimi, A., & Williamson, G. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500940 · Cited by 79
“This model involves activation of genes encoding molecules that promote a combination of lipid storage and lipogenesis leading to body-wide lipid repartitioning by increasing the triglyceride content of adipose tissue and lowering free fatty acids and triglycerides in the circulation, liver and muscle, thereby improvi…”
BackgroundGupta, R. A., Sarraf, P., Brockman, J. A., Shappell, S. B., Raftery, L. A., Willson, T. M., & DuBois, R. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208076200 · Cited by 74
Self-citationChen, L., Yang, B., McNulty, J. A., Clifton, L. G., Binz, J. G., Grimes, A. M., Strum, J. C., Harrington, W. W., Chen, Z., Balon, T. W., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.074088 · Cited by 74
“In our previous studies, we demonstrated that GI262570, a potent nonthiozolidinedione PPAR agonist (Willson et al., 2000), caused slow accumulation of sodium (sodium intake sodium excretion) (L. Chen, B. Yang, J. McNulty, L. Clifton, J. Binz, A. Grimes, J. Strum, W. Harrington, Z. Chen, T. Balon,…”
BackgroundUryu, S., Harada, J., HISAMOTO, M., & Oda, T. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03242-5 · Cited by 75
Safety of fibrates in cholestatic liver diseases
Carrion, A. F., Lindor, K. D., & Levy, C. (2021) · Liver International · doi:10.1111/liv.14871 · Cited by 71
Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
Liberopoulos, E. N., Florentin, M., Elisaf, M. S., Mikhailidis, D. P., & Tsianos, E. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010120 · Cited by 74
“The activity of fenofibrate on PPAR is stronger than that of bezafibrate,[17] while fenofibrate exhibits more favourable effects on lipid profile compared with bezafibrate [18, 19].”
BackgroundSalamone, S., Colin, C., Grillier‐Vuissoz, I., Kuntz, S., Mazerbourg, S., Flament, S., Martin, H., Richert, L., Chapleur, Y., & Boisbrun, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.044 · Cited by 73
Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis
Hashimoto, Y., & Miyachi, H. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.03.027 · Cited by 77
Phthalazin-1(2H)-one as a remarkable scaffold in drug discovery
Vila, N., Besada, P., Costas, T., Costas-Lago, M. C., & Terán, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.043 · Cited by 73
Mahindroo, N., Wang, C.-C., Liao, C. ‐., Huang, C.-F., Lu, I.-L., Lien, T., Peng, Y.-H., Huang, W., Lin, Y., Hsu, M.-C., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0510373 · Cited by 73
Gurnell, M. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.10.001 · Cited by 84
Nomura, M., Tanase, T., Ide, T., Tsunoda, M., Suzuki, M., Uchiki, H., Murakami, K., & Miyachi, H. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0205144 · Cited by 73
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
Loria, P., Lonardo, A., & Targher, G. (2008) · Clinical Science · doi:10.1042/cs20070311 · Cited by 72
Derosa, G., Maffioli, P., & Sahebkar, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.012 · Cited by 75
Damcott, C., Moffett, S. P., Feingold, E., Barmada, M. M., Marshall, J. A., Hamman, R. F., & Ferrell, R. E. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.010 · Cited by 85
Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy
Tobin, J. F., & Freedman, L. P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.07.004 · Cited by 77
Pickavance, L. C., Brand, C. L., Wassermann, K., & Wilding, J. P. H. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706041 · Cited by 71
“BF may not have had significant effects on most parameters because it is only a moderately weak PPARa agonist compared to fenofibrate in rodents, although potency in humans is approximately equivalent (Willson et al., 2000).”
BackgroundMeta-analysis of primary target genes of peroxisome proliferator-activated receptors
Heinäniemi, M., Uski, J. O., Degenhardt, T., & Carlberg, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r147 · Cited by 71
“The PPAR transcription factors are prominent players in the metabolic syndrome, because of their role as important regulators of lipid storage and catabolism [4].”
BackgroundObesity-induced chronic low-grade inflammation in adipose tissue: A pathway to Alzheimer’s disease
Zhai, W., Meng, Z., Chunxiao, W., Lingjie, M., Anguo, Z., Zhang, Y., Xinran, C., Yanjiao, X., & Li, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102402 · Cited by 76
“There are three subtypes of PPARs: PPAR α , PPAR γ , and PPAR β / δ (Willson et al., 2000; Grygiel-Gorniak, 2014; Dreyer et al., 1992).”
BackgroundNakano, R., Kurosaki, E., Yoshida, S., Yokono, M., Shimaya, A., Maruyama, T., & Shibasaki, M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.023 · Cited by 81
Oyama, T., Toyota, K., Waku, T., Hirakawa, Y., Nagasawa, N., Kasuga, J.-I., Hashimoto, Y., Miyachi, H., & Morikawa, K. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909015935 · Cited by 74
“Each PPAR subtype displays a distinct tissue distribution (Willson et al., 2000).”
BackgroundYamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 66
Molnár, F., Matilainen, M., & Carlberg, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502463200 · Cited by 72
PPARs in Inflammation, Atherosclerosis and Thrombosis
Duez, H., Fruchart, J., & Staels, B. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800402 · Cited by 77
Genetic loss or pharmacological blockade of testes-expressed taste genes causes male sterility
Mosinger, B., Redding, K. M., Parker, M. R., Yevshayeva, V., Yee, K. K., Dyomina, K., Li, Y., & Margolskee, R. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302827110 · Cited by 69
“Although clofibrate and other phenoxy compounds act on PPAR-α and perhaps several other off-targets (49, 50), we think that the block of TAS1R3 is the site of action that is important in male reproduction.”
MethodResultInfluentialChinetti-Gbaguidi, G., Rigamonti, E., Helin, L., Mutka, A. L., Lepore, M., Fruchart, J. C., Clavey, V., Ikonen, E., Lestavel, S., & Staels, B. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500326-jlr200 · Cited by 69
“that specifically activate human PPAR (18) were used.”
MethodCharacterization of the Species-Specificity of Peroxisome Proliferators in Rat and Human Hepatocytes
Ammerschlaeger, M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh071 · Cited by 70
“Willson, T. M. (2000). The PPARs: From Orphan Receptors to Drug Discovery.”
BackgroundXenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective
Wallace, B. D., & Redinbo, M. R. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.740049 · Cited by 73
“The three forms of PPAR (PPARα, PPARβ, and PPARγ) are lipid sensors and controllers of lipid homeostasis, adipocyte differentiation, development, metabolism, and tumorigenesis (Brown and Plutzky, 2007; Willson et al., 2000).”
Management strategies for acute spinal cord injury: current options and future perspectives
Stahel, P. F., VanderHeiden, T. F., & Finn, M. A. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32835a0e54 · Cited by 75
“Three subtypes of PPAR have been described (PPARa, PPARb/d and PPARg) which exhibit differential tissue distribution and ligand specificity [100].”
BackgroundJacobs, M. N., Dickins, M., & Lewis, D. F. V. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00021-9 · Cited by 83
Yun, S., Han, S., & Park, J. (2018) · PPAR Research · doi:10.1155/2018/6727421 · Cited by 74
“Ligand binding and activation of PPARγ result in heterodimer formation with the retinoid X receptor (RXR) and binding to a PPAR response element (PPRE) to regulate the transcription of numerous target genes [2, 3].”
BackgroundBrooks, D. A., Etgen, G. J., Rito, C. J., Shuker, A. J., Dominianni, S. J., Warshawsky, A. M., Ardecky, R., Paterniti, J. R., Tyhonas, J., Karanewsky, D. S., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0155188 · Cited by 73
Takayama, O., Yamamoto, H., Damdinsuren, B., Sugita, Y., Ngan, C. Y., Xu, X., Tsujino, T., Takemasa, I., Ikeda, M., Sekimoto, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603343 · Cited by 69
“To date, three PPAR isoforms, PPARa, PPARd/b, and PPARg, have been isolated (Willson et al, 2000).”
BackgroundSynthesis of the PPARβ/δ-selective agonist GW501516 and C4-thiazole-substituted analogs
Pereira, R., Gaudon, C., Iglesias, B., Germain, P., Gronemeyer, H., & de Lera, Á. R. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.060 · Cited by 69
Markt, P., Petersen, R. K., Flindt, E. N., Kristiansen, K., Kirchmair, J., Spitzer, G. M., Distinto, S., Schuster, D., Wolber, G., Laggner, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800128k · Cited by 68
Yue, L., Ye, F., Gui, C., Luo, H., Cai, J., Shen, J., Chen, K., Shen, X., & Jiang, H. (2005) · Protein Science · doi:10.1110/ps.04951405 · Cited by 68
“This is in agreement with the fact that Bezafibrate is a dual agonist of PPAR and PPAR (Willson et al. 2000).”
BackgroundInfluentialKato, M., Kusumi, T., Tsuchida, S., Tanaka, M., Sasaki, M., & Kudo, H. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0510-2 · Cited by 68
“There are three different members in the PPAR family identified to date, encoded by separate genes: PPARa, PPARb, and PPARc ( Willson et al. 2000 ).”
BackgroundInfluentialThe gene expression profile of extraskeletal myxoid chondrosarcoma
Subramanian, S., West, R. B., Marinelli, R. J., Nielsen, T. O., Rubin, B. P., Goldblum, J. R., Patel, R. M., Zhu, S., Montgomery, K. D., Ng, T., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1792 · Cited by 68
“The PPARG antagonist, GW9662 (2-chloro-5-nitro-N -phenylbenzamide), is cell-permeable, selective, and irreversible [93,94].”
BackgroundSoutham, A. D., Khanim, F. L., Hayden, R. E., Constantinou, J. K., Koczula, K. M., Michell, R. H., Viant, M. R., Drayson, M. T., & Bunce, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0202 · Cited by 70
“Both bezafibrate and MPA individually alter lipid metabolism (13, 14); however, nothing is known about their combinatorial effect on lipogenesis.”
The Natural Protective Mechanism Against Hyperglycemia in Vascular Endothelial Cells
Riahi, Y., Sin-Malia, Y., Cohen, G., Alpert, E., Gruzman, A., Eckel, J., Staels, B., Guichardant, M., & Sasson, S. (2010) · Diabetes · doi:10.2337/db09-1207 · Cited by 67
“X-ray analyses of crystal structures of the PPAR LBD identified a network of hydrogen bonds with His(413), Tyr(427), His(287), and Thr(253) that are involved in the binding interaction of eicosapentanoic acid (33).”
Koufany, M., Moulin, D., Bianchi, A., Muresan, M., Sebillaud, S., Netter, P., Weryha, G., & Jouzeau, J.-Y. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2354 · Cited by 66
“These data confirmed that agonists of PPARγ are potential therapeutic agents for arthritis [21,23,25,39], although they displayed a variable ability to activate this receptor subtype [39,43].”
BackgroundMouse KLF11 regulates hepatic lipid metabolism
Zhang, H., Chen, Q., Yang, M. H., Zhu, B., Cui, Y., Xue, Y., Gong, N., Cui, A., Wang, M., Shen, L., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.024 · Cited by 73
Peroxisome proliferator‐activated receptor (PPAR) modulators: Diabetes and beyond*
Jones, A. B. (2001) · Medicinal Research Reviews · doi:10.1002/med.1025 · Cited by 67
“The only currently de®ned biochemical activity is that of weak PPARa agonism (some ®brates may also possess lesser degrees of PPARg agonism, although the extent to which this might be clinically manifested is uncertain).(9,46) Direct investigation of PPARa, including studies with PPARa null mice, has implicated this t…”
Effects of fenofibrate on lipid parameters in obese rhesus monkeys
Winegar, D. A., Brown, P. J., Wilkison, W. O., Lewis, M. C., Ott, R. J., Tong, W. Q., Brown, H. R., Lehmann, J. M., Kliewer, S. A., Plunket, K. D., et al. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32207-0 · Cited by 67
Self-citationOyama, Y., Akuzawa, N., Nagai, R., & Kurabayashi, M. (2002) · Circulation Research · doi:10.1161/hh0202.103229 · Cited by 64
Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation
Willems, S., Zaienne, D., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00186 · Cited by 68
Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma
Shi, J., Wu, P., Sheng, L., Sun, W., & Zhang, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02389-7 · Cited by 72
The Lung Alveolar Lipofibroblast: An Evolutionary Strategy Against Neonatal Hyperoxic Lung Injury
Rehan, V. K., & Torday, J. S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5793 · Cited by 62
Yang, B., Brown, K. K., Chen, L., Carrick, K. M., Clifton, L. G., McNulty, J. A., Winegar, D. A., Strum, J. C., Stimpson, S. A., & Pahel, G. L. (2004) · BMC Pharmacology · doi:10.1186/1471-2210-4-23 · Cited by 74
“PPARγ agonists increase insulin sensitivity and circulating adiponectin [1,2,17,18].”
BackgroundInfluentialGiaginis, C., Giagini, A. T., & Theocharis, S. E. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.005 · Cited by 73
Koo, Y. D., Choi, J. W., Kim, M., Chae, S., Ahn, B. Y., Kim, M., Oh, B., Hwang, D., Seol, J. H., Kim, Y., et al. (2015) · Diabetes · doi:10.2337/db15-0115 · Cited by 68
Therapeutic approaches to drug targets in hyperlipidemia
Mahamuni, S. P., Khose, R. D., Menaa, F., & Badole, S. L. (2012) · Biomedicine · doi:10.1016/j.biomed.2012.08.002 · Cited by 72
“[63] Willson TM, Brown PJ, Sternbach DD, Henke BR.”
BackgroundSangshetti, J. N., Pathan, S. K., Patil, R. B., Ansari, S. A., Chhajed, S. S., Arote, R. B., & Shinde, D. B. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.050 · Cited by 66
In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones
Rakowitz, D., Maccari, R., Ottanà, R., & Vigorita, M. G. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.056 · Cited by 66
Novel 5-Substituted-1H-tetrazole Derivatives as Potent Glucose and Lipid Lowering Agents.
Momose, Y., Maekawa, T., Odaka, H., Ikeda, H., & Sohda, T. (2002) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.50.100 · Cited by 66
Controversy: PPARγ as a target for treatment of colorectal cancer
Gupta, R. A., & DuBois, R. N. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00486.2001 · Cited by 66
Peroxisome proliferator-activated receptors and angiogenesis
Biscetti, F., Straface, G., Pitocco, D., Zaccardi, F., Ghirlanda, G., & Flex, A. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.04.011 · Cited by 67
“In fact, rosiglitazone and pioglitazone have insulin-sensitizing and antidiabetic activity in humans with type 2 diabetes or impaired glucose tolerance [26].”
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.